Zacks Investment Research cut shares of Corium International Inc. (NASDAQ:CORI) from a hold rating to a sell rating in a report published on Friday.
According to Zacks, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. “
CORI has been the subject of a number of other research reports. FBR & Co restated a buy rating and set a $18.00 price objective on shares of Corium International in a research report on Tuesday, November 22nd. Needham & Company LLC restated a buy rating and set a $15.00 price objective on shares of Corium International in a research report on Monday, September 26th. Finally, Leerink Swann set a $16.00 price objective on Corium International and gave the company a buy rating in a research report on Tuesday, November 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $12.25.
Corium International (NASDAQ:CORI) opened at 5.51 on Friday. The firm’s 50-day moving average price is $5.02 and its 200-day moving average price is $4.72. The company’s market cap is $122.36 million. Corium International has a 52-week low of $3.14 and a 52-week high of $9.93.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. RTW Investments LLC raised its position in Corium International by 22.6% in the third quarter. RTW Investments LLC now owns 1,045,747 shares of the biopharmaceutical company’s stock valued at $5,888,000 after buying an additional 192,786 shares in the last quarter. Paloma Partners Management Co bought a new position in Corium International during the second quarter valued at approximately $152,000. Finally, Opaleye Management Inc. raised its position in Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock valued at $1,390,000 after buying an additional 5,000 shares in the last quarter. Institutional investors own 88.40% of the company’s stock.
About Corium International
Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.